Reversibilidad espirométrica en pacientes con enfermedad pulmonar obstructiva crónica: ¿debe emplearse 200 ó 400 µg de salbutamol?

Manríquez, Jorge; Díaz P., Orlando; Mendoza I., Laura; Borzone T., Gisella; Lisboa B., Carmen.
Rev. chil. enferm. respir ; 22(3): 168-175, sep. 2006. tab, graf
Artículo en Español | LILACS | ID: lil-453803

Documentos relacionados

  1. Regional lung response to bronchodilator reversibility testing determined by electrical impedance tomography in chronic obstructive pulmonary disease.
  2. Residual reversibility in COPD patients already on long-acting bronchodilator: The OscilloRevers Study.
  3. Acute Effect of Bronchodilator on Intrathoracic Airway Wall Compliance in COPD Patients.
  4. Dose Response to Transnasal Pulmonary Administration of Bronchodilator Aerosols via Nasal High-Flow Therapy in Adults with Stable Chronic Obstructive Pulmonary Disease and Asthma.
  5. Development of a novel digital breath-activated inhaler: Initial particle size characterization and clinical testing.
  6. Bronchodilator reversibility in asthma and COPD: findings from three large population studies.
  7. Salbutamol use in relation to maintenance bronchodilator efficacy in COPD: a prospective subgroup analysis of the EMAX trial.
  8. The association between chronic airflow obstruction and poverty in 12 sites of the multinational BOLD study.
  9. Duration of salmeterol-induced bronchodilation in mechanically ventilated chronic obstructive pulmonary disease patients: a prospective clinical study.
  10. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease. The TORCH experience.